Kuniyuki Aso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kuniyuki Aso has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Michihito Kono
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
4 shared publications Olga Amengual
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
4 shared publications- Yuichiro Fujieda
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
4 shared publications - Masaru Kato
The First Department of Internal Medicine, Faculty of Medicine, University of Toyama , Toyama
3 shared publications Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
3 shared publicationsHideki Kasahara
Department of Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan
2 shared publications
Latest Publications
- 21 August 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (8) , e70834
Association Between Fish Consumption and Minimal Disease Activity in Patients With Rheumatoid Arthritis Receiving Molecular‐Targeted Therapies
Aim: Diet may influence the clinical course of rheumatoid arthritis (RA). Consumption of fish, the main source of n‐3 polyunsaturated fatty acids (PUFAs), has been linked to decreased disease activity. We investigated the association between fish intake and disease activity in two different cohorts of RA patients receiving molecular‐targeted therapies. Methods: This retrospective cross‐sectional study included RA patients treated with biologics or Janus kinase inhibitors at Hokkaido University Hospital (Japan) and Virgen de las Nieves Hospital (Spain). Patients completed the validated brief‐type self‐administered diet history questionnaire (BDHQ, used with permission) and a custom‐designed detailed fish frequency questionnaire (DFFQ). Demographic, clinical, and laboratory data were obtained from medical records. Minimal disease activity (MDA) was defined as DAS28‐ESR < 2.6 and DAS28‐CRP < 2.4. Group comparisons and multivariate logistic regression analyses were performed. Results: In the Japanese cohort of 205 RA patients, 59% of patients met MDA criteria. Patients with MDA had a higher estimated daily intake of n‐3 PUFAs than those with non‐MDA. Multivariate logistic regression analysis identified weekly intake of n‐3 PUFA‐rich fish as an independent factor associated with MDA. In the Spanish RA cohort of 74 patients, 37% met MDA criteria. No significant differences in n‐3 PUFA intake or fish consumption were observed between MDA and non‐MDA groups. Conclusion: Consumption of n‐3 PUFA‐rich fish was associated with MDA in patients with RA receiving molecular‐targeted therapies.
- 21 August 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (8) , e70834
Association Between Fish Consumption and Minimal Disease Activity in Patients With Rheumatoid Arthritis Receiving Molecular‐Targeted Therapies
Aim: Diet may influence the clinical course of rheumatoid arthritis (RA). Consumption of fish, the main source of n‐3 polyunsaturated fatty acids (PUFAs), has been linked to decreased disease activity. We investigated the association between fish intake and disease activity in two different cohorts of RA patients receiving molecular‐targeted therapies. Methods: This retrospective cross‐sectional study included RA patients treated with biologics or Janus kinase inhibitors at Hokkaido University Hospital (Japan) and Virgen de las Nieves Hospital (Spain). Patients completed the validated brief‐type self‐administered diet history questionnaire (BDHQ, used with permission) and a custom‐designed detailed fish frequency questionnaire (DFFQ). Demographic, clinical, and laboratory data were obtained from medical records. Minimal disease activity (MDA) was defined as DAS28‐ESR < 2.6 and DAS28‐CRP < 2.4. Group comparisons and multivariate logistic regression analyses were performed. Results: In the Japanese cohort of 205 RA patients, 59% of patients met MDA criteria. Patients with MDA had a higher estimated daily intake of n‐3 PUFAs than those with non‐MDA. Multivariate logistic regression analysis identified weekly intake of n‐3 PUFA‐rich fish as an independent factor associated with MDA. In the Spanish RA cohort of 74 patients, 37% met MDA criteria. No significant differences in n‐3 PUFA intake or fish consumption were observed between MDA and non‐MDA groups. Conclusion: Consumption of n‐3 PUFA‐rich fish was associated with MDA in patients with RA receiving molecular‐targeted therapies.
- 21 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Fractional exhaled nitric oxide is a non-invasive disease activity marker of IgG4-related disease
Objectives: To evaluate the potential of fractional exhaled nitric oxide (FeNO) value in patients with IgG4-related disease (IgG4-RD) as a non-invasive disease activity marker. Methods: Patients fulfilling the 2019 ACR/EULAR classification criteria of IgG4-RD were enrolled. All patients who had never received oral glucocorticoids underwent FeNO measurement and computed tomography. Disease activity was evaluated using the IgG4-RD responder index (IgG4-RI). The cutoff for FeNO was set at 36 parts per billion (ppb), based on a Japanese normal upper limit. Spearman’s rank correlation was used to assess the association between FeNO values and clinical parameters. Receiver operating characteristic analysis was used to identify the involvement of specific organs. Results: A total of 35 patients (21 males, 72.0 [IQR 64.5, 77.0] years old) were enrolled. The median FeNO value was 48.0 [IQR 33.0, 99.5] ppb, with 23 (65.7%) patients exceeding the cutoff. The FeNO value was correlated with serum IgG4 levels (r = 0.48, P = 0.020), the number of organ involvements (r = 0.47, P = 0.020) and IgG4-RI (r = 0.47, P = 0.020). Dividing into two groups by the FeNO cutoff, lung involvement was more frequent in the high FeNO group (8.3% vs. 52.2%, P = 0.029). Area under the curve for the lung involvement was 0.88, and the optimal cutoff for identifying lung involvement using the Youden index was 55.2 ppb. Conclusion: FeNO value was elevated in patients with IgG4-RD and was associated with disease activity. Moreover, it can be associated with lung involvement.
- 21 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Fractional exhaled nitric oxide is a non-invasive disease activity marker of IgG4-related disease
Objectives: To evaluate the potential of fractional exhaled nitric oxide (FeNO) value in patients with IgG4-related disease (IgG4-RD) as a non-invasive disease activity marker. Methods: Patients fulfilling the 2019 ACR/EULAR classification criteria of IgG4-RD were enrolled. All patients who had never received oral glucocorticoids underwent FeNO measurement and computed tomography. Disease activity was evaluated using the IgG4-RD responder index (IgG4-RI). The cutoff for FeNO was set at 36 parts per billion (ppb), based on a Japanese normal upper limit. Spearman’s rank correlation was used to assess the association between FeNO values and clinical parameters. Receiver operating characteristic analysis was used to identify the involvement of specific organs. Results: A total of 35 patients (21 males, 72.0 [IQR 64.5, 77.0] years old) were enrolled. The median FeNO value was 48.0 [IQR 33.0, 99.5] ppb, with 23 (65.7%) patients exceeding the cutoff. The FeNO value was correlated with serum IgG4 levels (r = 0.48, P = 0.020), the number of organ involvements (r = 0.47, P = 0.020) and IgG4-RI (r = 0.47, P = 0.020). Dividing into two groups by the FeNO cutoff, lung involvement was more frequent in the high FeNO group (8.3% vs. 52.2%, P = 0.029). Area under the curve for the lung involvement was 0.88, and the optimal cutoff for identifying lung involvement using the Youden index was 55.2 ppb. Conclusion: FeNO value was elevated in patients with IgG4-RD and was associated with disease activity. Moreover, it can be associated with lung involvement.
- 3 July 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , e115-e116
Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma
- 3 July 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , e115-e116
Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma
- 17 March 2023
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (12) , 2832-2833
Scrofuloderma and Miliary Tuberculosis in a Patient Taking Adalimumab
- 17 March 2023
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (12) , 2832-2833
Scrofuloderma and Miliary Tuberculosis in a Patient Taking Adalimumab
- Top Cited PapersOpen Access
- 27 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming
Dysregulation of Th17 and Treg cells contributes to the pathophysiology of many autoimmune diseases. Herein, we show that itaconate, an immunomodulatory metabolite, inhibits Th17 cell differentiation and promotes Treg cell differentiation by orchestrating metabolic and epigenetic reprogramming. Mechanistically, itaconate suppresses glycolysis and oxidative phosphorylation in Th17- and Treg-polarizing T cells. Following treatment with itaconate, the S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and 2-hydroxyglutarate levels are decreased by inhibiting the synthetic enzyme activities in Th17 and Treg cells, respectively. Consequently, these metabolic changes are associated with altered chromatin accessibility of essential transcription factors and key gene expression in Th17 and Treg cell differentiation, including decreased RORγt binding at the Il17a promoter. The adoptive transfer of itaconate-treated Th17-polarizing T cells ameliorates experimental autoimmune encephalomyelitis. These results indicate that itaconate is a crucial metabolic regulator for Th17/Treg cell balance and could be a potential therapeutic agent for autoimmune diseases.
- 27 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Top Cited PapersOpen AccessItaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming
Dysregulation of Th17 and Treg cells contributes to the pathophysiology of many autoimmune diseases. Herein, we show that itaconate, an immunomodulatory metabolite, inhibits Th17 cell differentiation and promotes Treg cell differentiation by orchestrating metabolic and epigenetic reprogramming. Mechanistically, itaconate suppresses glycolysis and oxidative phosphorylation in Th17- and Treg-polarizing T cells. Following treatment with itaconate, the S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and 2-hydroxyglutarate levels are decreased by inhibiting the synthetic enzyme activities in Th17 and Treg cells, respectively. Consequently, these metabolic changes are associated with altered chromatin accessibility of essential transcription factors and key gene expression in Th17 and Treg cell differentiation, including decreased RORγt binding at the Il17a promoter. The adoptive transfer of itaconate-treated Th17-polarizing T cells ameliorates experimental autoimmune encephalomyelitis. These results indicate that itaconate is a crucial metabolic regulator for Th17/Treg cell balance and could be a potential therapeutic agent for autoimmune diseases.
- 1 February 2023
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (2) , 400-401
Anti-EJ antibody-positive antisynthetase syndrome developed pulmonary arterial hypertension 7 years after the onset of disease: the necessity of periodic evaluation
Letters to the Editor; Authors: K. Aso, H. Kasahara
- 1 February 2023
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (2) , 400-401
Anti-EJ antibody-positive antisynthetase syndrome developed pulmonary arterial hypertension 7 years after the onset of disease: the necessity of periodic evaluation
Letters to the Editor; Authors: K. Aso, H. Kasahara
- 24 January 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (3) , 411-423
Inhibitor of NF‐κB Kinase Subunit ε Contributes to Neuropsychiatric Manifestations in Lupus‐Prone Mice Through Microglial Activation
Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multiorgan dysfunction. Neuropsychiatric SLE (NPSLE) occurs in 30–40% of lupus patients and is the most severe presentation of SLE, frequently resulting in limitation of daily life. Recent studies have shown that microglia, tissue‐resident macrophages in the central nervous system, are involved in the pathogenesis of NPSLE. This study was undertaken to explore new therapeutic targets for NPSLE focusing on microglia.Methods: RNA sequencing of microglia in MRL/lpr, lupus‐prone mice, as well as that of microglia cultured in vitro with cytokines were performed. A candidate gene, which could be a therapeutic target for NPSLE, was identified, and its role in microglial activation and phagocytosis was investigated using specific inhibitors and small interfering RNA. The effect of intracerebroventricular administration of the inhibitor on the behavioral abnormalities of MRL/lpr was also evaluated.Results: Transcriptome analysis revealed the up‐regulation of Ikbke, which encodes the inhibitor of NF‐κB kinase subunit ɛ (IKBKε) in both microglia from MRL/lpr mice and cytokine‐stimulated microglia in vitro. Intracerebroventricular administration of an IKBKε inhibitor ameliorated cognitive function and suppressed microglial activation in MRL/lpr mice. Mechanistically, IKBKε inhibition reduced glycolysis, which dampened microglial activation and phagocytosis.Conclusion: These findings suggest that IKBKε plays a vital role in the pathogenesis of NPSLE via microglial activation, and it could serve as a therapeutic target for NPSLE.
- 24 January 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (3) , 411-423
Inhibitor of NF‐κB Kinase Subunit ε Contributes to Neuropsychiatric Manifestations in Lupus‐Prone Mice Through Microglial Activation
Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multiorgan dysfunction. Neuropsychiatric SLE (NPSLE) occurs in 30–40% of lupus patients and is the most severe presentation of SLE, frequently resulting in limitation of daily life. Recent studies have shown that microglia, tissue‐resident macrophages in the central nervous system, are involved in the pathogenesis of NPSLE. This study was undertaken to explore new therapeutic targets for NPSLE focusing on microglia.Methods: RNA sequencing of microglia in MRL/lpr, lupus‐prone mice, as well as that of microglia cultured in vitro with cytokines were performed. A candidate gene, which could be a therapeutic target for NPSLE, was identified, and its role in microglial activation and phagocytosis was investigated using specific inhibitors and small interfering RNA. The effect of intracerebroventricular administration of the inhibitor on the behavioral abnormalities of MRL/lpr was also evaluated.Results: Transcriptome analysis revealed the up‐regulation of Ikbke, which encodes the inhibitor of NF‐κB kinase subunit ɛ (IKBKε) in both microglia from MRL/lpr mice and cytokine‐stimulated microglia in vitro. Intracerebroventricular administration of an IKBKε inhibitor ameliorated cognitive function and suppressed microglial activation in MRL/lpr mice. Mechanistically, IKBKε inhibition reduced glycolysis, which dampened microglial activation and phagocytosis.Conclusion: These findings suggest that IKBKε plays a vital role in the pathogenesis of NPSLE via microglial activation, and it could serve as a therapeutic target for NPSLE.
- 16 January 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (8) , 1114-1115
Homonymous hemianopsia and headache with mass-like lesion
- 16 January 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (8) , 1114-1115
Homonymous hemianopsia and headache with mass-like lesion
- 31 December 2022
- Published by Elsevier in Gastroenterology
- Vol. 165 (2) , E15-E17
Disseminated Ulcerative Nodules With Elevated Liver Enzymes
- 31 December 2022
- Published by Elsevier in Gastroenterology
- Vol. 165 (2) , E15-E17
Disseminated Ulcerative Nodules With Elevated Liver Enzymes
- 7 July 2020
- Published by SAGE Publications in Lupus
- Vol. 29 (10) , 1238-1247
Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus
This study aimed to explore the risk factors for ‘severe’ neuropsychiatric (NP) flare in patients with systemic lupus erythematosus (SLE). This retrospective study comprised newly diagnosed 184 adult SLE patients who visited Hokkaido University Hospital between 2006 and 2017. In this study, severe NP flare was defined as the occurrence of at least one newly developed British Isles Lupus Assessment Group A score in the neurological domain. Overall severe NP flare-free survival was estimated by Kaplan–Meier analysis. Clinical and demographic profiles at SLE diagnosis were assessed as potential risk items in the adjusted multivariate Cox regression model. The median follow-up period was 7.9 years (interquartile range (IQR) 4.6–12.3) years. A total of 28 (15.2%) patients had one or more severe NP flares during the observation period. The median time from patient enrolment date to severe NP flare occurrence was 3.1 years (IQR 0.9–6.3 year). The 2- and 10-year severe NP flare-free survival rates were 92.7% and 86.0%, respectively. Among the manifestations of severe NP flare, psychosis was the most frequent (19.1%). In the multivariate model, low serum levels of C4 (hazard ratio (HR) = 3.67, p = 0.013) and severe NP manifestations at SLE diagnosis (HR = 7.11, p < 0.001) emerged as independent risk factors for developing severe NP flare. The first severe NP flare presented early in the course of SLE. Low C4 level and severe NP manifestations at SLE diagnosis could predict the development of severe NP flare.
- 7 July 2020
- Published by SAGE Publications in Lupus
- Vol. 29 (10) , 1238-1247
Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus
This study aimed to explore the risk factors for ‘severe’ neuropsychiatric (NP) flare in patients with systemic lupus erythematosus (SLE). This retrospective study comprised newly diagnosed 184 adult SLE patients who visited Hokkaido University Hospital between 2006 and 2017. In this study, severe NP flare was defined as the occurrence of at least one newly developed British Isles Lupus Assessment Group A score in the neurological domain. Overall severe NP flare-free survival was estimated by Kaplan–Meier analysis. Clinical and demographic profiles at SLE diagnosis were assessed as potential risk items in the adjusted multivariate Cox regression model. The median follow-up period was 7.9 years (interquartile range (IQR) 4.6–12.3) years. A total of 28 (15.2%) patients had one or more severe NP flares during the observation period. The median time from patient enrolment date to severe NP flare occurrence was 3.1 years (IQR 0.9–6.3 year). The 2- and 10-year severe NP flare-free survival rates were 92.7% and 86.0%, respectively. Among the manifestations of severe NP flare, psychosis was the most frequent (19.1%). In the multivariate model, low serum levels of C4 (hazard ratio (HR) = 3.67, p = 0.013) and severe NP manifestations at SLE diagnosis (HR = 7.11, p < 0.001) emerged as independent risk factors for developing severe NP flare. The first severe NP flare presented early in the course of SLE. Low C4 level and severe NP manifestations at SLE diagnosis could predict the development of severe NP flare.